Onartuzumab
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
Product Specifications
CAS Number
1133766-06-9
Product Name Alternative
MetMAb
UNSPSC
12352203
Target
C-Met/HGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/onartuzumab.html
Purity
99.62
Solubility
10 mM in DMSO
Smiles
[Onartuzumab]
Molecular Weight
(98.907 kDa)
References & Citations
[1]Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110 (32) :E2987-96.|[2]Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165 (1) :186-197.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA750988 100 µL
Histone H3 (tri methyl K27) Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
BNC882719-100 1x 100 µL
P53 (Tumor Suppressor Protein) (TP53/2719), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details